Safety profile of conjugated linoleic acid in a 12-month trial in obese humans.
Quick navigation
Link to full study
http://www.ncbi.nlm.nih.gov/pubmed/15354322
Conclusion of this study
At biweekly visits, subjects completed a questionnaire evaluating side effects and adverse events. Blood was taken for assay of liver function, glucose, insulin, serum lipids, blood counts, and general chemistry. Overall, body composition did not differ between groups. Laboratory tests showed no adverse effects of CLA. Adverse events and side effects were less in the CLA group compared to placebo. We conclude that CLA as Clarinol is safe for use in obese humans for at least one year.
Supplements analyzed in this study
|
Health conditions analyzed in this study
No health conditions information for this study.Functions related to this study
|
||
|
Body systems related to this study
 Cardiovascular System |
